Search Thermo Fisher Scientific
Disclaimer
Clicking the images or links will redirect you to a website hosted by BenchSci that provides third-party scientific content. Neither the content nor the BenchSci technology and processes for selection have been evaluated by us; we are providing them as-is and without warranty of any kind, including for use or application of the Thermo Fisher Scientific products presented.
Leinco Technologies
CTLA-4 (Ipilimumab) Recombinant Human Monoclonal Antibody (MDX-010), Functional Grade, Fc Muted™
Product Details
LT1605-500UG
Applications
Tested Dilution
Publications
Product Specifications
Species Reactivity
Human
Host/Isotype
Human
/ IgG1, kappa
Expression System
HEK293 cells
Class
Recombinant Monoclonal
Type
Antibody
Clone
MDX-010
Immunogen
Human CTLA-4
Conjugate
Form
Liquid
Concentration
≥5.0 mg/mL
Purification
Protein A/G
Storage buffer
PBS, pH 7.2-7.4
Contains
no preservative
Storage conditions
4°C short term, -80°C long term
Shipping conditions
Wet ice
Product Specific Information
Specificity: This non-therapeutic biosimilar antibody uses the same variable region sequence as the therapeutic antibody Ipilimumab. Ipilimumab binds to Human CTLA-4.
Endotoxin Level: <1.0 EU/mg as determined by the LAL method.
Purity: ≥95% monomer by analytical SEC.
Preparation: Functional grade preclinical antibodies are manufactured in an animal free facility using in vitro cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.
Pathogen Testing: To protect mouse colonies from infection by pathogens and to assure that experimental preclinical data is not affected by such pathogens, all of Leinco recombinant biosimilar antibodies are tested and guaranteed to be negative for all pathogens in the IDEXX IMPACT I Mouse Profile.
Storage: Functional grade biosimilar antibodies may be stored sterile as received at 2-8C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80C. Avoid Repeated Freeze Thaw Cycles.
Target Information
Ipilimumab (Yervoy) is a humanized monoclonal antibody that is approved by the U.S. Food and Drug Administration for the treatment of patients with unresectable or metastatic melanoma. Ipilimumab works to activate the immune system by targeting CTLA-4 (Cytotoxic T-lymphocyte protein 4), a negative regulator of cytotoxic T-lymphocyte activity. Ipilimumab binds to CTLA-4, blocking the inhibitory signal, which allows the cytotoxic T-lymphocytes to destroy the cancer cells.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
References (0)
Have you cited this product in a publication?
Let us know so we can reference it here.
Bioinformatics
Protein Aliases: BMS-734016; MDX-010; MDX-CTLA-4; Yervoy
Performance Guarantee
If an Invitrogen™ antibody doesn't perform as described on our website or datasheet,we'll replace the product at no cost to you, or provide you with a credit for a future purchase.*
Learn more
We're here to help
Get expert recommendations for common problems or connect directly with an on staff expert for technical assistance related to applications, equipment and general product use.
Contact tech support